Antimicrobial Technologies Group (ATG), a start-up technology company that develops additives capable of killing germs associated with conditions like the H1N1 flu and athlete’s foot, officially opened its doors in Sioux Falls.
ATG held a ribbon-cutting ceremony at the Graduate Education and Research Center on the Sioux Falls University Center campus.
“ATG is a great example of a company that is commercializing research that started at South Dakota’s universities,” Gov. Mike Rounds said. “It’s arrangements like these that are helping South Dakota become a recognized leader in research and technology.”
The ribbon-cutting event marks ATG’s grand opening, although the company has been in business for about six months. The company currently has five employees and plans to hire more in the near future. The first applications of ATG’s product will be applied to socks for diabetics and athletes.
The technology is the result of Dr. Yuyu Sun’s pioneering research at the University of South Dakota. Sun recently received the President’s Award for Innovation & Entrepreneurship.
“We came to South Dakota because this is where the research and university are. We have since found that South Dakota and Sioux Falls are excellent places to do business. There is a great workforce and great people with the right skill sets,” said Simon Johnston, CEO, ATG.
“There are a number of related companies doing business in South Dakota already that we could potentially partner with. Everything about doing business in South Dakota makes a great deal of sense,” Johnston concluded.
Other applications for ATG’s product include military uniforms and undergarments; personal protection garments for health care workers, such as face masks, scrubs and lab coats; hospital linens and incontinence pads; surface protection in paints, caulk and resins; medical and dental tubing; industrial applications; and food service applications.
-30-
Contact:
Mary Lehecka Nelson
Marketing and Public Relations Manager
605-773-3301
|
|
Advertisement |
|
|
International Stem Cell Corporation Announces Collaboration with Scripps Research Institute’s Center for Regenerative Medicine to Study Parthenogenetic Stem Cells 
